When a small biotech start-up approached Worldwide to navigate the complexities of a Phase I study on an antibody-drug conjugate (ADC) for advanced solid tumors, specifically non-small cell lung cancer, we stepped up to the challenge. With a tight timeline for First Patient In (FPI) and the need for flexible protocol adjustments, our experienced team implemented a strategic site selection approach, fostering strong relationships with investigators and sites.
Explore how our tailored solutions can support your ADC development program and find out how we were able to achieve FPI in only six weeks in this case study.